Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Teva Pharmaceutical Industries ADR
(NY:
TEVA
)
16.76
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, May 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Teva Pharmaceutical Industries ADR
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Catalyst Pharma The No. 1 Biotech, Just Crushed 2023 Guidance Estimates
March 15, 2023
The guidance includes Catalyst's newest, and second, product.
Via
Investor's Business Daily
7 Core Stocks to Build a Solid Portfolio Around
March 13, 2023
You’ll enjoy your investing journey more if you know that you can rely on your core of stocks to buy to provide a solid foundation.
Via
InvestorPlace
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
March 09, 2023
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
Via
News Direct
BRTX's ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
March 08, 2023
Metabolism is the chemical process whereby the body produces energy from food. By breaking down carbohydrates and fats into sugars, the cells access fuel that can be used or stored via the liver or...
Via
Benzinga
Why Teva Pharmaceutical Stock Is Sliding Today
February 08, 2023
Investors were disappointed with the drugmaker's 2023 outlook.
Via
The Motley Fool
Teva Pharmaceutical Stock Dives On Fourth-Quarter Miss, Light 2023 Guidance
February 08, 2023
The company missed fourth-quarter estimates and issued light guidance.
Via
Investor's Business Daily
Analyst Ratings for Teva Pharmaceutical Indus
January 19, 2023
Via
Benzinga
3 Dirt Cheap Stocks to Buy in January
January 14, 2023
Bargains can easily be found as the new year gets underway.
Via
The Motley Fool
Better Generics Pharmaceutical Stock: Teva or Viatris?
March 05, 2023
Both have plans to return to growth.
Via
The Motley Fool
7 Smart Stock Picks for Cautious Investors
February 28, 2023
As market volatility continues, consider playing it safe with these seven high-quality stocks for cautious investors.
Via
InvestorPlace
Walmart, Home Depot And 3 Stocks To Watch Heading Into Tuesday
February 21, 2023
With US futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
A Patent Cliff Is Coming For Bristol — Can Billions In New Products Fill The Gap?
February 17, 2023
The company's biggest moneymakers are soon to lose patent protection.
Via
Investor's Business Daily
Axsome Therapeutics (AXSM) Stock Falls as Teva Pursues Generic Depression Drug
February 13, 2023
Axsome Therapeutics (AXSM) stock is taking a beating on Monday as rival Teva Pharmaceutical (TEVA) prepares a generic depression drug.
Via
InvestorPlace
Teva Plots Its Knockoff Of Axsome's New Depression Drug, Sending The Biotech Sprawling
February 13, 2023
The company only just gained approval for its depression drug in August.
Via
Investor's Business Daily
Teva Pharmaceutical Industries (TEVA) Q4 2022 Earnings Call Transcript
February 08, 2023
TEVA earnings call for the period ending December 31, 2022.
Via
The Motley Fool
Teva Pharma Posts Lower Q4 Earnings, FY23 Outlook Within Expectations
February 08, 2023
Via
Benzinga
Nasdaq Bear Market: 3 Tantalizing Value Stocks That Can Double Your Money by 2026
February 08, 2023
These profitable companies are exceptionally cheap and ripe for the picking, following a 33% decline in the Nasdaq Composite.
Via
The Motley Fool
The 7 Best Growth Stocks to Buy for February 2023
February 06, 2023
Some of the best growth stocks are lesser-known names that have the ability to provide tremendous long-term upside for investors.
Via
InvestorPlace
Stock Market Rally Powers Higher Amid Big Earnings From Tesla, Boeing, Microsoft, American Express: Weekly Review
January 27, 2023
Stocks reacted well to uneven earnings and economic reports.
Via
Investor's Business Daily
Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed?
January 26, 2023
Things aren't as bad as they might seem.
Via
The Motley Fool
6 Great Stocks to Buy in 2023 and Hold Forever
January 26, 2023
I own all six great businesses and don't plan to sell a single share.
Via
The Motley Fool
How Former IBD 50 Leader Catalyst Pharma Is Trying To Claw Back From A 29% Setback
January 25, 2023
Catalyst is adding to its portfolio with a $160 million deal.
Via
Investor's Business Daily
Nasdaq Bear Market: 3 Screaming Bargains That Can Double Your Money by 2025
January 25, 2023
A 33% plunge in the Nasdaq Composite is the opportune time to scoop up these exceptional deals.
Via
The Motley Fool
Dow, Nasdaq Boasting Triple-Digit Midday Lead
January 23, 2023
Investors seem intent on leaving last week's losses behind, as earnings season heats up.
Via
Talk Markets
Catalyst Pharma Shares Take A Hit As Teva Files For Generic Version Of Its Lead Product
January 23, 2023
Via
Benzinga
No. 1 IBD 50 Stock Catalyst Tanks As Teva Looks To Knock Off Its Only Product
January 23, 2023
Shares have sat atop the IBD 50 for weeks, have perfect ratings and recently hit a profit-taking zone.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2023
January 19, 2023
Via
Benzinga
Tesla To Rally Around 138%? Here Are 10 Other Analyst Forecasts For Thursday
January 19, 2023
JP Morgan cut the price target for Apple Inc. (NASDAQ: AAPL) from $190 to $180. JP Morgan analyst Samik Chatterjee maintained an Overweight rating. Apple shares fell 1.1% to $133.70 in pre-market...
Via
Benzinga
Organon Stock Scores Market Leadership With Jump To 83 RS Rating
January 17, 2023
Organon sees its Relative Strength Rating reach the 80-plus level.
Via
Investor's Business Daily
If You Invested $1,000 in Novavax In 2020, This Is How Much You Would Have Today
January 13, 2023
The stock has gone on a wild ride over the past few years.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.